First Wave BioPharma CEO James Sapirstein to Moderate Panel Discussion at Longwood Healthcare Leaders Fall Webconference
September 14, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Sept. 14, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation
September 07, 2022 07:00 ET
|
First Wave BioPharma, Inc.
Data suggest technology provides improved delayed-release profile that ensures adrulipase is delivered to targeted areas of the GI tract First Wave BioPharma expects to initiate Phase 2 trial...
First Wave BioPharma Announces AAPS 2022 PharmSci 360 Accepts Adrulipase Formulation Abstract
August 31, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Aug. 31, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022
August 29, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Aug. 29, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma, Inc. Announces Reverse Stock Split
August 25, 2022 12:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Aug. 25, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma, Inc. Announces Private Placement
July 15, 2022 08:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., July 15, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
Fecal Pancreatic Elastase Testing Market Is Set to Expand at A CAGR Of 7.7% To Reach US$ 30.2 Million By the Year 2032: FMI
April 20, 2022 11:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
Companies Profiled in Fecal Pancreatic Elastase Testing Market are Laboratory Corporation of America® Holdings, DiaSorin, ScheBo Biotech AG, Immundiagnostik AG, Invivo Healthcare, DRG Instruments...
First Wave BioPharma Provides Update on Adrulipase (FW-EPI) Clinical Program
January 13, 2022 07:00 ET
|
First Wave BioPharma, Inc.
Company filed two provisional patent applications for new enteric granule formulation of adrulipase and for related nutritional indications in new patient populations “Adrulipase Alfa” approved by...
AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)
August 18, 2021 07:05 ET
|
AzurRx BioPharma, Inc.
MS1819 and PERT combination therapy achieves primary and secondary outcome measure endpointsStudy data indicates clinically meaningful improvement in coefficient of fat absorption (CFA) primary...
AzurRx BioPharma Announces WHO Publication of “Adrulipase Alfa” as International Nonproprietary Name for MS1819
August 17, 2021 07:00 ET
|
AzurRx BioPharma, Inc.
BOCA RATON, Fla., Aug. 17, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies...